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B

loodstream infections (BSI) have a significant impact on morbidity and mortality in the general population. It is estimated
that over 500,000 individuals develop BSI annually in the United
States, leading to nearly 75,000 deaths (1). Appropriate antimicrobial therapy is essential to reduce the burden of BSI, since inappropriate antimicrobial therapy has been associated with increased mortality (2–5).
Adjustment for the acute severity of illness has been emphasized as an important tool for the examination of the impact of
inappropriate antimicrobial therapy in patients with BSI (6). A
risk score recently has been derived and validated to predict the
outcome of patients at the time of diagnosis of Gram-negative BSI.
The BSI mortality risk score (BSIMRS) has a high discriminative
ability to predict the prognosis of patients with Gram-negative BSI
in both referral and population-based settings (7, 8). The BSIMRS
is based on acute severity of illness, as summarized by the Pitt
bacteremia score (9), source of infection, and major underlying
medical conditions that are independently associated with mortality (Table 1). There is a substantial increase in predicted 28-day
mortality following Gram-negative BSI as the BSIMRS increases
from 0 to 16 (7, 8).
The current retrospective cohort study examined the overall
impact of inappropriate empirical antimicrobial therapy on 28day mortality in patients with Gram-negative BSI. The impact of
inappropriate antimicrobial therapy was stratified by predicted
prognosis at initial presentation using predefined BSIMRS categories. Additionally, a predictive model of mortality was developed based on BSIMRS and appropriateness of empirical antimicrobial therapy.
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MATERIALS AND METHODS
Setting. The study was conducted at Palmetto Health Richland and Baptist Hospitals in Columbia, SC, USA. The two hospitals have a combined
total of over 1,100 licensed beds and provide care in a wide variety of
medical and surgical subspecialties for local residents of Richland County,
as well as for regional referrals from within the state of South Carolina
(http://www.palmettohealth.org).
Definitions. Gram-negative BSI was defined as the growth of any aerobic Gram-negative bacillus in a blood culture. Monomicrobial BSI was
defined as the growth of only one species of a microorganism in a blood
culture, and polymicrobial BSI was defined as the growth of more than
one microorganism in a blood culture. The primary source of BSI was
defined according to the Centers for Disease Control and Prevention
(CDC) criteria (10). Cancer was defined as a current diagnosis of a malignant tumor, excluding skin basal and squamous cell carcinoma. Liver
cirrhosis was defined based on clinical, laboratory, ultrasonography, or
histopathology results, when available (11). Mortality was defined as
death or discharge to hospice within 28 days of the onset of BSI. Empirical
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The bloodstream infection mortality risk score (BSIMRS) predicts the outcome of patients with Gram-negative bloodstream
infections (BSI) with high discrimination. This retrospective cohort study examined the impact of inappropriate antimicrobial
therapy on mortality in adult patients with Gram-negative BSI admitted to Palmetto Health Hospitals in Columbia, SC, USA,
from 1 January 2011 to 31 December 2012 after stratification by predicted prognosis at initial presentation using BSIMRS. A
multivariate Cox regression model was used to identify independent risk factors for 28-day mortality overall and within each
predefined BSIMRS category (<5, 5 to 9, and >10). Relative risk reduction (RRR), absolute risk reduction (ARR), and number
needed to treat (NNT) were calculated from a predictive logistic regression model of mortality. Overall, 390 unique patients with
first episodes of Gram-negative BSI were identified. The median age was 66 years, and 229 (59%) were women. There was significant association between inappropriate antimicrobial therapy and mortality in patients with BSIMRS of 5 to 9 (adjusted hazard
ratio [aHR], 3.55; 95% confidence intervals [CI], 1.22 to 8.31; P ⴝ 0.02) and BSIMRS of >10 (aHR, 4.99; 95% CI, 1.09 to 22.87;
P ⴝ 0.04) but not in those with BSIMRS of <5 (aHR, 3.34; 95% CI, 0.17 to 22.77; P ⴝ 0.34). RRR, ARR, and NNT were 0.25, 0.02,
and 63 for BSIMRS of <5; 0.56, 0.32, and 3 for BSIMRS of 5 to 9; and 0.39, 0.39, and 3 for BSIMRS of >10, respectively. There is a
significant benefit from appropriate antimicrobial therapy in patients with Gram-negative BSI with guarded (BSIMRS of 5 to 9)
and poor (BSIMRS of >10) predicted prognosis. Survival difference remains unclear among those with good predicted prognosis
(BSIMRS of <5) at initial presentation.

Cain et al.

Variable

Point allocation

Malignancy
Liver cirrhosis
High-inoculum infectiona

3
4
4

Pitt bacteremia scoreb
0-1
2-3
ⱖ4

0
2
5

a
High-inoculum infection indicates a source of infection other than urinary tract or
central venous catheter.
b
Pitt bacteremia score is calculated based on temperature (35.1-36 or 39.0-39.9°C, 1
point; ⱕ35 or ⱖ40°C, 2 points), blood pressure (hypotension, 2 points), mental status
(disorientation, 1 point; stupor, 2 points; coma, 4 points), respiratory status
(mechanical ventilation, 2 points), and cardiac status (cardiac arrest, 4 points). The
worst reading is recorded on the day the first positive blood culture is obtained or the
day before for nosocomial bloodstream infections.
c
Modified from Al-Hasan et al. (8) with permission of the publisher.

antimicrobial therapy was defined as antimicrobial agents received within
the first 48 h following the collection of the first set of positive blood
cultures. Empirical antimicrobial therapy was considered appropriate if it
met all of the following criteria: (i) patient received at least the minimum
recommended dose of an antimicrobial agent according to the medication
package insert for creatinine clearance at the time of BSI; (ii) the empirical
antimicrobial agent was administered via the intravenous route, with the
exception of fluoroquinolones, which were considered appropriate if administered orally in hemodynamically stable patients due to relatively
high oral bioavailability; (iii) bloodstream isolate was susceptible to an
empirical antimicrobial agent based on in vitro antimicrobial susceptibility testing results using Clinical Laboratory and Standards Institute
(CLSI) guidelines. Of note, ampicillin, ampicillin-sulbactam, and firstgeneration cephalosporins were considered inappropriate for treatment
of BSI due to chromosomally mediated AmpC-producing Enterobacteriaceae (CAE). However, third-generation cephalosporins were considered
appropriate for CAE if the bloodstream isolate was susceptible to these
agents in vitro by CLSI standards. All penicillins and cephalosporins were
considered inappropriate for treatment of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae regardless of in vitro antimicrobial susceptibility testing results. Similarly, all beta-lactams were considered inappropriate for carbapenemase-producing Enterobacteriaceae.
Case ascertainment. In this retrospective cohort study, we identified
all patients with BSI due to aerobic Gram-negative bacilli from 1 January
2011 to 31 December 2012 through microbiology laboratory databases at
Palmetto Health. We included 390 unique hospitalized adults with first
episodes of monomicrobial BSI caused by aerobic Gram-negative bacilli
in the study. Patients ⬍18 years old (n ⫽ 62), with polymicrobial BSI (n ⫽
79), with recurrent episodes of BSI (n ⫽ 24), and who were treated outside
the hospital (n ⫽ 23) were excluded.
Statistical analysis. Descriptive statistics were used to summarize the
data: medians and interquartile ranges (IQR) for continuous variables
and counts and percentages for categorical variables. Cox proportional
hazards regression was used to identify risk factors for mortality. Patients
were monitored for 28 days after the onset of BSI or until death or discharge to hospice. This enabled us to censor patients who were lost to
follow-up between discharge and 28 days from the date of obtaining initial
blood cultures. Patients who were lost to follow-up before 28 days were
censored at the date of last health care encounter. In order to identify
independent risk factors for mortality, variables were included in a multivariate Cox model if the P value for a univariate association with mortality was ⱕ0.10. The components of the BSIMRS were analyzed as one
continuous variable in the final model according to the total point allocation in the BSIMRS. The proportional hazards assumption was evaluated

246 aac.asm.org

by plotting the log-integrated hazard versus time from the Kaplan-Meier
method. Hazard ratios (HR) with 95% confidence intervals (CI) were
presented to demonstrate the strength of association between each risk
factor and mortality.
Patients were stratified based on the predicted prognosis at the time of
diagnosis of Gram-negative BSI using the BSIMRS (⬍5, 5 to 9, and ⱖ10).
These three categories were predefined based on the discriminative ability
of BSIMRS in a previous study (8). The impact of inappropriate antimicrobial therapy on mortality was examined in each group using KaplanMeier survival analysis. The log-rank P value was used to assess the statistical significance in survival between patients who received appropriate
and inappropriate empirical antimicrobial therapy in each group. Multivariate Cox proportional hazards regression was used to allow adjustments for age and independent risk factors for mortality other than
BSIMRS and antimicrobial therapy, if any.
Finally, logistic regression was used to develop a predictive model of
mortality in patients with Gram-negative BSI who were monitored for 28
days based on BSIMRS and the appropriateness of empirical antimicrobial therapy after adjustments for age and other independent risk factors
of mortality, if any. Predicted probabilities obtained directly from the
logistic regression model were plotted by BSIMRS to visualize the estimated risk of mortality in patients who received appropriate and inappropriate empirical antimicrobial therapy. The predicted probabilities of
mortality with 95% CI were calculated from logistic regression models for
each of the three BSIMRS categories. Relative risk reduction (RRR), absolute risk reduction (ARR), and number needed to treat (NNT) were
reported to estimate the potential benefit from appropriate antimicrobial
therapy.
JMP (version 10.0; SAS Institute Inc., Cary, NC, USA) was used for
statistical analysis. The level of significance for statistical testing was defined as P ⬍ 0.05 (2-sided) unless otherwise specified.

RESULTS

Over the 2-year study period, we identified 390 unique adult patients with first episodes of Gram-negative BSI, 257 (66%) from
Palmetto Health Richland Hospital and 133 (34%) from Palmetto
Health Baptist Hospital. The median age was 66 years, and 229
(59%) were women. The urinary tract was the most common
source of infection, and Escherichia coli was the most common
bloodstream isolate (Table 2).
During 28 days of follow-up from the onset of Gram-negative
BSI, 53 patients died, 6 were discharged to hospice, 281 survived,
and 50 were lost to follow-up. The results of univariate Cox proportional hazards regression for risk factors of mortality are
shown in Table 3. Age, BSIMRS, and inappropriate empirical antimicrobial therapy were independently associated with mortality
in the multivariate Cox proportional hazards regression model.
There was nearly a 40% increase in mortality for each decade
increase in age and for each point increase in BSIMRS. There was
a nearly 3-fold increase in the risk of mortality in patients with
Gram-negative BSI who received inappropriate empirical antimicrobial therapy (Table 4).
Among 390 patients with Gram-negative BSI, 214, 158, and 18
had BSIMRS of ⬍5, 5 to 9, and ⱖ10, respectively. In Kaplan-Meier
analyses, inappropriate antimicrobial therapy was associated with
increased risk of mortality in patients with BSIMRS of 5 to 9 and
ⱖ10 (P ⫽ 0.02 and 0.008, respectively). However, there was no
significant association between inappropriate antimicrobial therapy and mortality in patients with BSIMRS of ⬍5 (P ⫽ 0.26) (Fig.
1). The same results were demonstrated with the multivariate Cox
proportional hazards model after adjustment for age. For patients
with BSIMRS of 5 to 9 and ⱖ10, inappropriate empirical antimicrobial therapy was associated with a nearly 3- and 5-fold increase
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TABLE 1 Bloodstream infection mortality risk scorec

Antimicrobial Therapy for Bloodstream Infections

TABLE 3 Univariate Cox model results for risk factors of mortality in
Gram-negative bloodstream infection

Variable

Value (n ⫽ 390)

Variablea

Hazard ratio

95% CI

P value

Age in years, median (IQR)
Female gender, n (%)

66 (55-78)
229 (59)

Ethnicity, n (%)
White
African-American
Other

191 (49)
188 (48)
11 (3)

Diabetes mellitus, n (%)
End-stage renal disease, n (%)
Liver cirrhosis, n (%)
Cancer, n (%)

144 (37)
38 (10)
6 (2)
70 (18)

Age (per decade)
Female gender
White ethnicity
Diabetes mellitus
End-stage renal disease
Transplant recipient
HIV infection
Nursing home resident
Recent hospitalization
Nosocomial acquisition

1.37
0.67
1.83
0.50
0.83
0.93
0.72
1.47
1.25
1.46

1.16-1.65
0.40-1.11
1.09-3.15
0.27-0.89
0.29-1.86
0.16-2.97
0.04-3.28
0.76-2.63
0.71-2.11
0.77-2.60

⬍0.001
0.12
0.02
0.02
0.67
0.92
0.73
0.24
0.43
0.23

Immunocompromised host, n (%)
Chemotherapy
Neutropenia
Transplant recipient
HIV infection

62 (16)
36 (9)
15 (4)
15 (4)
9 (2)

1.39
4.42
5.18
2.37

1.29-1.51
1.08-12.0
3.10-8.66
1.42-3.99

⬍0.001
0.04
⬍0.001
0.001

Site of infection acquisition, n (%)
Community acquired
Healthcare associated
Nosocomial

BSIMRS (per point)
Liver cirrhosis
Cancer
Nonurinary/CVC source
Pitt bacteremia score
0-1
2-3
ⱖ4

Referenceb
3.49
10.77

1.34-9.72
4.90-28.40

0.005
⬍0.001

161 (41)
159 (41)
70 (18)

Inappropriate antimicrobial therapy

2.94

1.40-5.55

0.006

Microbiology, n (%)
Escherichia coli
Klebsiella species
Proteus species
Pseudomonas aeruginosa
Enterobacter species
Other

207 (53)
77 (20)
31 (8)
20 (5)
19 (5)
36 (9)

Primary source of infection, n (%)
Urinary tract
Gastrointestinal tract
Respiratory tract
Central venous catheter
Skin and soft tissue
Other
Unknown

216 (55)
50 (13)
12 (3)
35 (9)
17 (4)
8 (2)
52 (13)

Pitt bacteremia score, median (IQR)
BSIMRS, median (IQR)

2 (1-4)
4 (2-6)

Inappropriate antimicrobial therapy, n (%)
Beta-lactam monotherapya
Fluoroquinoloneb or aminoglycoside monotherapya
Beta-lactam plus fluoroquinoloneb or aminoglycosidea
Other antimicrobial classes or combinationsa

31 (8)
12/211 (6)
5/64 (8)
5/104 (5)
9/11 (82)

a
Data show the number of inappropriate regimens/total per antimicrobial class or
combination (percentage of inappropriate regimens).
b
Including 7 and 4 patients who received oral fluoroquinolones either as monotherapy
or in combination with beta-lactams, respectively.

in mortality, respectively. However, in patients with BSIMRS of
⬍5, there was no significant increase in mortality in association
with inappropriate empirical antimicrobial therapy (Table 5).
The predicted probability of mortality at the time of diagnosis
of Gram-negative BSI based on BSIMRS and antimicrobial therapy, after age adjustment, is illustrated in Fig. 2. Predicted mortality in patients who received appropriate and inappropriate empir-
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a

CVC, central venous catheter.
Pitt bacteremia score was analyzed as a categorical variable, with scores of 2-3 and ⱖ4
compared to a reference score of 0-1.
b

ical antimicrobial therapy appears comparable until the BSIMRS
exceeds 3. Afterwards, there is a substantial increase in predicted
mortality in patients who received inappropriate empirical antimicrobial therapy compared to those who received appropriate
therapy.
The overall predicted probability of mortality was low in the
BSIMRS ⬍5 category, with overlapping 95% CIs between appropriate and inappropriate antimicrobial therapy (Table 6). On the
other hand, there was a substantial reduction in predicted mortality
with appropriate antimicrobial therapy in groups with BSIMRS of 5
to 9 and ⱖ10, as estimated by both RRR and ARR. The NNT with
appropriate antimicrobial therapy for Gram-negative BSI was nearly
3 in the latter two BSIMRS groups.
DISCUSSION

This is the third study to demonstrate that Gram-negative BSI is a
spectrum of illness with a wide variation in prognosis, as predicted
by the BSIMRS. Whereas the initial derivation and validation cohorts in Minnesota included a predominantly white population
(7, 8), the current study in South Carolina included a more diverse
ethnic population.
Appropriate antimicrobial therapy is essential in patients with
Gram-negative BSI (2–5). Adjustment for acute severity of illness
TABLE 4 Multivariate Cox model results for independent risk factors of
mortality in Gram-negative bloodstream infection
Variable

aHR

95% CI

P value

Age (per decade)
White ethnicity
Diabetes mellitus
BSIMRS (per point)
Inappropriate antimicrobial therapy

1.41
1.15
0.65
1.41
3.54

1.18-1.70
0.68-2.00
0.34-1.16
1.30-1.54
1.67-6.82

⬍0.001
0.60
0.15
⬍0.001
0.002
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TABLE 2 Clinical characteristics of patients with Gram-negative
bloodstream infection

Cain et al.

infection mortality risk score and empirical antimicrobial therapy. P values
were calculated using a log-rank test from Kaplan-Meier survival curves.

has been advocated in prior reviews (6). However, the precise
estimation of the impact of appropriate empirical antimicrobial
therapy on outcome remains difficult due to the influence of variables other than acute severity of illness and antimicrobial therapy
(12). The current study demonstrates that the outcome of patients
with Gram-negative BSI is dictated mostly by major host factors,
source of infection, and the acute severity of illness at initial presentation, as summarized by the BSIMRS. Appropriate empirical
antimicrobial therapy influences the outcome of patients within
each BSIMRS category (⬍5, 5 to 9, and ⱖ10), but the impact of
initial prognosis remains more substantial. For example, patients
with a BSIMRS of ⬍5 have a predicted mortality of ⬍10% even if
they receive inappropriate empirical therapy. On the other hand,
patients with BSIMRS of 5 to 9 and ⱖ10 have a predicted mortality
of nearly 25% and 60%, respectively, when treated with appropriate empirical antimicrobial therapy (Table 6). This difference in
predicted prognosis at initial presentation likely explains why
some patients survive despite receiving inappropriate antimicrobial therapy, while others expire despite receiving appropriate
therapy.
The results of this study confirm that there is an overall
survival benefit from appropriate empirical antimicrobial therapy in Gram-negative BSI after adjustments for potential confounders. However, after stratification by predicted prognosis
using BSIMRS, most of this benefit is observed in patients with
guarded (BSIMRS of 5 to 9) and poor predicted (BSIMRS of ⱖ10)
prognosis. Whether there is a survival difference in patients with
good predicted prognosis (BSIMRS of ⬍5) at initial presentation
remains unclear. This may explain the lack of significant difference in mortality among patients with BSI who received appropri-

TABLE 5 Impact of inappropriate antimicrobial therapy on mortality in
Gram-negative bacteremia after stratification by BSIMRS

FIG 2 Predicted mortality following Gram-negative bacteremia by bloodstream infection mortality risk score and empirical antimicrobial therapy. The
size of the marker for point estimates is weighted approximately by the relative
number of subjects with the corresponding risk score.

ate and inappropriate empirical antimicrobial agents in prior
studies, particularly when the majority of included patients had a
urinary source of infection (13–16).
The overall NNT with appropriate antimicrobial therapy in
patients with BSI was estimated to be nearly 8 in a recent metaanalysis (3). The current study demonstrated that the NNT varied
by predicted prognosis at the diagnosis of BSI. The NNT was
nearly 3 in patients with BSIMRS of 5 to 9 and ⱖ10. On the other
hand, in patients with BSIMRS of ⬍5, the NNT with appropriate
antimicrobial therapy was 63. In addition, the relative risk reduction also was lower in patients with BSIMRS of ⬍5 compared to
those of patients with BSIMRS of 5 to 9 and ⱖ10 (Table 6). This
overall lower benefit from appropriate antimicrobial therapy in
patients with BSIMRS of ⬍5 compared to those with BSIMRS of
ⱖ5 should be taken into consideration when making empirical
antimicrobial treatment decisions in individual patients or developing clinical management guidelines.
Many medical centers publish institutional antibiograms to
help local health care providers choose empirical antimicrobial
therapy for treatment of suspected infections, including BSI.
However, the choice of an appropriate threshold for the selection
of an antimicrobial agent is left to the health care provider. The
current work provides an objective tool to enhance the utility of
such antibiograms. In an era of increasing antimicrobial resistance
and limited availability of effective antimicrobial agents for treatment of serious Gram-negative infections, it is imperative to maximize the benefit-to-risk ratio of antimicrobial therapy in order to
TABLE 6 Predicted probabilities of mortality with and without
appropriate antimicrobial therapy in Gram-negative bacteremia by
BSIMRS
Mortality (95% CI) by therapy type

BSIMRS

aHR

95% CI

P value

BSIMRS

Inappropriate

Appropriate

RRR

ARR

NNT

⬍5
5-9
ⱖ10

3.34
3.55
4.99

0.17-22.77
1.22-8.31
1.09-22.87

0.34
0.02
0.04

⬍5
5-9
ⱖ10

0.07 (0.04-0.10)
0.58 (0.46-0.69)
0.99 (0.86-1.00)

0.05 (0.04-0.06)
0.25 (0.22-0.28)
0.61 (0.52-0.69)

0.246
0.558
0.392

0.016
0.321
0.390

63
3.1
2.6
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FIG 1 Outcome of patients with Gram-negative bacteremia by bloodstream
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and 5% alpha error). Alternatively, softer endpoint variables
could be used instead of mortality to examine the outcome of
patients with BSIMRS of ⬍5, such as length of stay in the hospital
or predefined criteria for treatment cure (21, 22). It would be
useful to standardize these definitions across the medical literature and use clinical cure criteria that correlate with either survival
or shorter length of hospitalization.
In summary, the BSIMRS is an excellent tool to predict the
prognosis of patients with Gram-negative BSI based on acute severity of illness, primary source of infection, and major host comorbidities. Appropriate empirical antimicrobial therapy is essential to improve the outcome of patients with Gram-negative
BSI. However, the impact of appropriate therapy seems higher in
patients with guarded (BSIMRS of 5 to 9) and poor (BSIMRS of
ⱖ10) predicted prognoses than in those with good predicted
prognosis (BSIMRS of ⬍5) at initial presentation. The BSIMRS
provides an objective tool to improve the selection of empirical
antimicrobial therapy, in addition to local antimicrobial resistance rates and risk factors for antimicrobial resistance.
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improve overall outcomes. Given higher benefit from appropriate
antimicrobial therapy in patients with BSIMRS of ⱖ5 compared
to those with BSIMRS of ⬍5, it is reasonable to use an arbitrary
susceptibility of ⱖ95% for BSIMRS of ⱖ5 and ⱖ90% for BSIMRS
of ⬍5, for example.
In addition, stratification of patients with Gram-negative BSI
based on prognosis as predicted by BSIMRS provides a tool to
improve the use of empirical antimicrobial agents in patients with
suspected BSI due to Gram-negative bacilli that harbor antimicrobial resistance genes. Prior studies have identified patients at risk
of BSI due to Pseudomonas aeruginosa and fluoroquinolone-resistant and ESBL-producing Enterobacteriaceae based on the number
of individual risk factors for antimicrobial resistance or the summation of the weighted score for each risk factor (17–20). The
decision to expand antimicrobial coverage may appear less complex in patients with no or multiple risk factors for antimicrobial
resistance. However, many patients fall in the intermediate category where they have only one risk factor or two low-weight risk
factors. Using the BSIMRS to stratify patients based on predicted
prognosis may enhance the performance and utility of such risk
scores, as it incorporates the potential benefit from appropriate
antimicrobial therapy with the risk of antimicrobial resistance in
order to help make a better treatment decision. For example, in a
population with an overall prevalence of 3% for ESBL-producing
Enterobacteriaceae among bloodstream isolates, the nonstratified
use of carbapenems for the empirical treatment of BSI is a lowyield intervention in patients with BSIMRS of ⬍5. It would require treating 2,100 (63/0.03) patients with carbapenems in this
population to potentially save one life. On the other hand, if carbapenems were used in patients with BSIMRS of ⱖ5 and intermediate or high risk for BSI due to ESBL-producing Enterobacteriaceae
(15% and 30% probabilities, respectively, as previously estimated
[20]), the NNT with carbapenems may be as low as 20 (3/0.15) and 10
(3/0.3), respectively.
The inclusion of patients with BSI from two large medical centers that provide health care for a large proportion of residents of
Richland County, SC, USA, is a strength of this study. The diversity of the Richland County population increases the generalizability of the study results. Stratification of patients based on predicted prognosis at initial presentation is a unique feature of this
study, as it provides a scientific method to precisely estimate the
effect of empirical antimicrobial therapy on the outcome of patients with Gram-negative BSI.
Our study has limitations. First, it is a retrospective cohort
study with variables collected retrospectively. However, all variables in the study, including those in the BSIMRS, were clearly
predefined prior to data collection. Second, although two hospitals were included, both were located in the same geographical
area and belong to the same health care system. Including patients
from multiple hospitals in different areas would add variety to the
population and prescription practices. Third, it remains possible
that the study is underpowered in the detection of a difference in
mortality in patients with BSIMRS of ⬍5 who received appropriate and inappropriate antimicrobial therapy, and a larger sample
size is required to reexamine this group in future studies. However, given the low mortality in patients with BSIMRS of ⬍5, an
adequately powered study to detect a relatively small difference in
mortality between appropriate and inappropriate therapy in this
group would require the enrollment of thousands of patients (850
patients in the inappropriate therapy arm, assuming 80% power
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